Literature DB >> 31189728

Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.

Jonathan Oliva1, Scott Galasinski1, Amelia Richey1, Amy E Campbell1, Marvin J Meyers1, Neal Modi1, Jun Wen Zhong1, Rabi Tawil1, Stephen J Tapscott1, Francis M Sverdrup2.   

Abstract

Facioscapulohumeral muscular dystrophy (FSHD) is characterized by misexpression of the double homeobox 4 (DUX4) developmental transcription factor in mature skeletal muscle, where it is responsible for muscle degeneration. Preventing expression of DUX4 mRNA is a disease-modifying therapeutic strategy with the potential to halt or reverse the course of disease. We previously reported that agonists of the β-2 adrenergic receptor suppress DUX4 expression by activating adenylate cyclase to increase cAMP levels. Efforts to further explore this signaling pathway led to the identification of p38 mitogen-activated protein kinase as a major regulator of DUX4 expression. In vitro experiments demonstrate that clinically advanced p38 inhibitors suppress DUX4 expression in FSHD type 1 and 2 myoblasts and differentiating myocytes in vitro with exquisite potency. Individual small interfering RNA-mediated knockdown of either p38α or p38β suppresses DUX4 expression, demonstrating that each kinase isoform plays a distinct requisite role in activating DUX4 Finally, p38 inhibitors effectively suppress DUX4 expression in a mouse xenograft model of human FSHD gene regulation. These data support the repurposing of existing clinical p38 inhibitors as potential therapeutics for FSHD. The surprise finding that p38α and p38β isoforms each independently contribute to DUX4 expression offers a unique opportunity to explore the utility of p38 isoform-selective inhibitors to balance efficacy and safety in skeletal muscle. We propose p38 inhibition as a disease-modifying therapeutic strategy for FSHD. SIGNIFICANCE STATEMENT: Facioscapulohumeral muscular dystrophy (FSHD) currently has no treatment options. This work provides evidence that repurposing a clinically advanced p38 inhibitor may provide the first disease-modifying drug for FSHD by suppressing toxic DUX4 expression, the root cause of muscle degeneration in this disease.
Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31189728      PMCID: PMC6652132          DOI: 10.1124/jpet.119.259663

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  89 in total

1.  p38 MAPK signaling regulates recruitment of Ash2L-containing methyltransferase complexes to specific genes during differentiation.

Authors:  Shravanti Rampalli; LiFang Li; Esther Mak; Kai Ge; Marjorie Brand; Stephen J Tapscott; F Jeffrey Dilworth
Journal:  Nat Struct Mol Biol       Date:  2007-11-18       Impact factor: 15.369

2.  Generation of isogenic D4Z4 contracted and noncontracted immortal muscle cell clones from a mosaic patient: a cellular model for FSHD.

Authors:  Yvonne D Krom; Julie Dumonceaux; Kamel Mamchaoui; Bianca den Hamer; Virginie Mariot; Elisa Negroni; Linda N Geng; Nicolas Martin; Rabi Tawil; Stephen J Tapscott; Baziel G M van Engelen; Vincent Mouly; Gillian S Butler-Browne; Silvère M van der Maarel
Journal:  Am J Pathol       Date:  2012-08-04       Impact factor: 4.307

3.  Hematopoietic protein tyrosine phosphatase mediates beta2-adrenergic receptor-induced regulation of p38 mitogen-activated protein kinase in B lymphocytes.

Authors:  Jaclyn W McAlees; Virginia M Sanders
Journal:  Mol Cell Biol       Date:  2008-12-01       Impact factor: 4.272

4.  A MyoD-generated feed-forward circuit temporally patterns gene expression during skeletal muscle differentiation.

Authors:  Bennett H Penn; Donald A Bergstrom; F Jeffrey Dilworth; Eyal Bengal; Stephen J Tapscott
Journal:  Genes Dev       Date:  2004-10-01       Impact factor: 11.361

Review 5.  β2-Adrenergic agonists and the treatment of skeletal muscle wasting disorders.

Authors:  Olivier R Joassard; Anne-Cécile Durieux; Damien G Freyssenet
Journal:  Int J Biochem Cell Biol       Date:  2013-07-08       Impact factor: 5.085

6.  Establishment of clonal myogenic cell lines from severely affected dystrophic muscles - CDK4 maintains the myogenic population.

Authors:  Guido Stadler; Jennifer Cj Chen; Kathryn Wagner; Jerome D Robin; Jerry W Shay; Charles P Emerson; Woodring E Wright
Journal:  Skelet Muscle       Date:  2011-03-08       Impact factor: 4.912

7.  Chromatin-wide and transcriptome profiling integration uncovers p38α MAPK as a global regulator of skeletal muscle differentiation.

Authors:  Jessica Segalés; Abul B M M K Islam; Roshan Kumar; Qi-Cai Liu; Pedro Sousa-Victor; F Jeffrey Dilworth; Esteban Ballestar; Eusebio Perdiguero; Pura Muñoz-Cánoves
Journal:  Skelet Muscle       Date:  2016-03-15       Impact factor: 4.912

8.  Neuromuscular electrical stimulation promotes development in mice of mature human muscle from immortalized human myoblasts.

Authors:  Paraskevi Sakellariou; Andrea O'Neill; Amber L Mueller; Guido Stadler; Woodring E Wright; Joseph A Roche; Robert J Bloch
Journal:  Skelet Muscle       Date:  2016-02-27       Impact factor: 4.912

9.  The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial.

Authors:  Marie Fisk; Joseph Cheriyan; Divya Mohan; Julia Forman; Kaisa M Mäki-Petäjä; Carmel M McEniery; Jonathan Fuld; James H F Rudd; Nicholas S Hopkinson; David A Lomas; John R Cockcroft; Ruth Tal-Singer; Michael I Polkey; Ian B Wilkinson
Journal:  PLoS One       Date:  2018-03-22       Impact factor: 3.240

10.  DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy?

Authors:  Alexandra Tassin; Dalila Laoudj-Chenivesse; Céline Vanderplanck; Marietta Barro; Sébastien Charron; Eugénie Ansseau; Yi-Wen Chen; Jacques Mercier; Frédérique Coppée; Alexandra Belayew
Journal:  J Cell Mol Med       Date:  2012-12-04       Impact factor: 5.310

View more
  24 in total

Review 1.  FSHD Therapeutic Strategies: What Will It Take to Get to Clinic?

Authors:  Charis L Himeda; Peter L Jones
Journal:  J Pers Med       Date:  2022-05-25

Review 2.  Therapeutic Approaches in Facioscapulohumeral Muscular Dystrophy.

Authors:  Justin Cohen; Alec DeSimone; Monkol Lek; Angela Lek
Journal:  Trends Mol Med       Date:  2020-10-19       Impact factor: 11.951

3.  Longitudinal measures of RNA expression and disease activity in FSHD muscle biopsies.

Authors:  Chao-Jen Wong; Leo H Wang; Seth D Friedman; Dennis Shaw; Amy E Campbell; Chris B Budech; Leann M Lewis; Richard J F L Lemmers; Jeffrey M Statland; Silvère M van der Maarel; Rabi N Tawil; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2020-04-15       Impact factor: 6.150

4.  Applying genome-wide CRISPR-Cas9 screens for therapeutic discovery in facioscapulohumeral muscular dystrophy.

Authors:  Angela Lek; Yuanfan Zhang; Keryn G Woodman; Shushu Huang; Alec M DeSimone; Justin Cohen; Vincent Ho; James Conner; Lillian Mead; Andrew Kodani; Anna Pakula; Neville Sanjana; Oliver D King; Peter L Jones; Kathryn R Wagner; Monkol Lek; Louis M Kunkel
Journal:  Sci Transl Med       Date:  2020-03-25       Impact factor: 17.956

Review 5.  Current Therapeutic Approaches in FSHD.

Authors:  Leo H Wang; Rabi Tawil
Journal:  J Neuromuscul Dis       Date:  2021

Review 6.  Promising Perspective to Facioscapulohumeral Muscular Dystrophy Treatment: Nutraceuticals and Phytochemicals.

Authors:  Ceren Hangül; Sibel Berker Karaüzüm; Esra Küpeli Akkol; Devrim Demir-Dora; Zafer Çetin; Eyüp İlker Saygılı; Gökhan Evcili; Eduardo Sobarzo-Sánchez
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

7.  Induction of a local muscular dystrophy using electroporation in vivo: an easy tool for screening therapeutics.

Authors:  Aline Derenne; Alexandra Tassin; Thuy Hang Nguyen; Estelle De Roeck; Vincianne Jenart; Eugénie Ansseau; Alexandra Belayew; Frédérique Coppée; Anne-Emilie Declèves; Alexandre Legrand
Journal:  Sci Rep       Date:  2020-07-09       Impact factor: 4.379

Review 8.  The ties that bind: functional clusters in limb-girdle muscular dystrophy.

Authors:  Elisabeth R Barton; Christina A Pacak; Whitney L Stoppel; Peter B Kang
Journal:  Skelet Muscle       Date:  2020-07-29       Impact factor: 4.912

Review 9.  The prospects of targeting DUX4 in facioscapulohumeral muscular dystrophy.

Authors:  Linde F Bouwman; Silvère M van der Maarel; Jessica C de Greef
Journal:  Curr Opin Neurol       Date:  2020-10       Impact factor: 6.283

Review 10.  p38 MAPKs - roles in skeletal muscle physiology, disease mechanisms, and as potential therapeutic targets.

Authors:  Christopher M Brennan; Charles P Emerson; Jane Owens; Nicolas Christoforou
Journal:  JCI Insight       Date:  2021-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.